32.49
1.50%
0.4393
Akero Therapeutics Inc stock is traded at $32.49, with a volume of 232.19K.
It is up +1.50% in the last 24 hours and up +15.19% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$32.05
Open:
$31.76
24h Volume:
232.19K
Relative Volume:
0.48
Market Cap:
$2.20B
Revenue:
-
Net Income/Loss:
$-179.27M
P/E Ratio:
-12.69
EPS:
-2.56
Net Cash Flow:
$-155.88M
1W Performance:
+2.52%
1M Performance:
+15.19%
6M Performance:
+65.47%
1Y Performance:
+123.12%
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-22-24 | Resumed | BofA Securities | Neutral |
Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
Aug-28-23 | Initiated | UBS | Buy |
Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-10-21 | Initiated | BofA Securities | Buy |
Feb-26-21 | Initiated | Guggenheim | Buy |
Sep-10-20 | Initiated | Morgan Stanley | Overweight |
Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
Mar-02-20 | Initiated | H.C. Wainwright | Buy |
Feb-10-20 | Initiated | Canaccord Genuity | Buy |
Jul-15-19 | Initiated | Evercore ISI | Outperform |
Jul-15-19 | Initiated | JP Morgan | Overweight |
Jul-15-19 | Initiated | Jefferies | Buy |
Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Akero Therapeutics COO sells $1.6 million in stock - Investing.com India
Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $1,601,104.12 in Stock - MarketBeat
Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock By Investing.com - Investing.com Canada
Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock - Investing.com India
abrdn plc Sells 75,879 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 4,515 Shares of Stock - MarketBeat
Akero Therapeutics chief development officer sells $651,960 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics chief development officer sells $651,960 in stock - Investing.com
Akero Therapeutics (NASDAQ:AKRO) Trading Up 5.8%Here's What Happened - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Decline in Short Interest - MarketBeat
Akero Therapeutics to Present Data Reinforcing the Efficacy - GlobeNewswire
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 - StockTitan
Akero Therapeutics Insiders Sell US$1.2m Of Stock, Possibly Signalling Caution - Simply Wall St
(AKRO) Proactive Strategies - Stock Traders Daily
Andrew Cheng Sells 24,992 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Akero Therapeutics CEO Andrew Cheng sells $2.88 million in stock By Investing.com - Investing.com Canada
Akero Therapeutics chief development officer sells $636,490 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics chief development officer sells $636,490 in stock - Investing.com India
State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares - GuruFocus.com
Akero therapeutics COO Jonathan Young sells $1.2 million in stock By Investing.com - Investing.com Australia
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Rheos Capital Works Inc. - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Decrease in Short Interest - MarketBeat
Akero therapeutics COO Jonathan Young sells $1.2 million in stock - Investing.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 6,136 Shares - MarketBeat
Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin - Insider Monkey
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds - Insider Monkey
Should investors be concerned about Akero Therapeutics Inc (AKRO)? - US Post News
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
10 Most Promising Small-Cap Stocks According to Hedge Funds - Insider Monkey
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
The Manufacturers Life Insurance Company Purchases 22,195 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Inc [AKRO] Investment Appeal on the Rise - Knox Daily
AKRO’s 2023 Market Dance: Up 20.56% – Time to Invest? - The InvestChronicle
Akero Therapeutics (NASDAQ:AKRO) Shares Up 4.2%Here's Why - MarketBeat
A better buy-in window may exist right now for Akero Therapeutics Inc (AKRO) - SETE News
A company insider recently sold 10,000 shares of Akero Therapeutics Inc [AKRO]. Should You Sale? - Knox Daily
Algert Global LLC Decreases Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics COO sells $281,770 in company stock - Investing.com
Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $281,800.00 in Stock - MarketBeat
Is Akero Therapeutics Inc (AKRO) a good investment opportunity? - US Post News
The Potential Rise in the Price of Akero Therapeutics Inc (AKRO) following insiders activity - Knox Daily
INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Longview News-Journal
Top investors say Akero Therapeutics Inc (AKRO) ticks everything they need - SETE News
Perceptive Advisors LLC Purchases 112,426 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference - StockTitan
Akero Therapeutics Inc (AKRO) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
(AKRO) Investment Analysis and Advice - Stock Traders Daily
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus.com
A company insider recently sold 5,500 shares of Akero Therapeutics Inc [AKRO]. Should You Sale? - Knox Daily
Akero Therapeutics (NASDAQ:AKRO) Trading Down 2.7% - MarketBeat
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):